Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Access to medicines and treatment
Third-line ARVs could widen treatment gap in Zimbabwe

HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.

Published
12 March 2013
From
IRIN Plus News
Treatment-experienced people
Redefining Expanded Access Programs for patients with MDR-HIV

It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

Published
04 December 2012
From
GMHC Treatment Issues
Changing treatment
Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

Published
13 November 2012
From
International AIDS Society
Resistance
Mutation breaks HIV's resistance to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

Published
14 September 2012
From
Science Daily
Treatment-experienced people
Booster HIV Drug Can Be Dropped

In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.

Published
13 September 2012
From
MedPage Today
New and experimental HIV treatments
ViiV Announces Expanded Access to Once-a-Day Integrase Inhibitor ... But Activists Are Concerned About Its Potential Misuse

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare's investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy.

Published
09 March 2012
From
The Body
New and experimental HIV treatments
EACS: Does Maraviroc Intensification Promote Better CD4 Cell Recovery?

Adding maraviroc (Selzentry or Celsentri) to a suppressive antiretroviral regimen may help promote CD4 T-cell recovery in a subset of patients who experience poor immunological response to treatment, according to 2 studies presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.

Published
27 October 2011
From
HIVandhepatitis.com
Treatment-experienced people
HIV Drug Resistance Effect Damped Down over Time

The proportion of HIV patients who are able to suppress the virus despite extensive drug resistance nearly tripled over a 10-year period, researchers reported.

Published
10 October 2011
From
MedPage Today
Treatment-experienced people
Low stock: HIV patients denied second-line drugs

About 750 HIV patients requiring advanced treatment in the state are forced to go without life-saving second-line anti-retroviral therapy (ART) drugs which are in short supply.

Published
07 August 2011
From
Times of India
Treatment-experienced people
Is there a future for HIV-infected patients in deep salvage?

Most of us built resistance as we joined study after study that exposed us to functional monotherapy. In fact, I consider many of us who have been struggling with multiple drug resistance to be wounded soldiers from a time when we were recruited into studies we joined out of desperation to access a new drug.

Published
04 May 2011
From
The Body
← First12Next →

Filter by country